BLOG/🇺🇸United States··daily

US IPO Pipeline SEC S-1 Filings — March 24, 2026

IPO Pipeline

4 high priority4 total filings analysed

Executive Summary

Four S-1 filings on March 24, 2026, underscore a diverse IPO pipeline: a new SPAC (Research Alliance Corp III), post-IPO amendment for Forgent Power Solutions (IPO closed Feb 6), proposed IPO for Arxis, and resale registration for biotech Artelo Biosciences amid distress signals. Overarching themes include standard SPAC protections, acquisition-driven asset buildup in power sector (FPS intangibles from PwrQ/States/VanTran/MGM), extensive regulatory/compliance risks (Arxis FCPA/ITAR/FAA), and dilution/Nasdaq pressures (Artelo 1-for-3 reverse split reducing shares 65% from 2.12M to 736K). No uniform period-over-period trends across filings, but FPS flags Q4 2025 customer concentration risk in revenue/accounts receivable, contrasting neutral sentiment in SPAC/FPS vs negative in Arxis and mixed in Artelo. Critical developments like FPS over-allotment options (Feb 9) and Artelo Nasdaq extension to March 30 imply near-term catalysts, with high materiality (9-10/10) signaling investor attention. Portfolio-level pattern: 75% neutral/mixed sentiment suggests resilient IPO momentum despite biotech distress, positioning SPACs/power plays for alpha amid aerospace/biotech hurdles.

Tracking the trend? Catch up on the prior US IPO Pipeline SEC S-1 Filings digest from March 23, 2026.

Investment Signals(12)

  • Forgent Power Solutions↓(BULLISH)
    ▲

    Successful IPO closing Feb 6, 2026, followed by private placements and over-allotment options Feb 9, indicating strong post-IPO demand and float management

  • Research Alliance Corp III↓(BULLISH)
    ▲

    5M Class A shares IPO at $10/share with 24-month business combination window and sponsor/management redemption waivers, standard for efficient de-SPAC

  • Forgent Power Solutions↓(BULLISH)
    ▲

    Acquisitions (PwrQ, States, VanTran, MGM) built intangible assets including customer relationships, trade names, and production backlog vs no prior comparable

  • Artelo Biosciences↓(BULLISH)
    ▲

    Nasdaq compliance extension to March 30, 2026, for $2.5M minimum equity, averting immediate delisting after reverse split

  • Research Alliance Corp III↓(BULLISH)
    ▲

    Redemption threshold at 1.71M shares (34.2% of 5M public shares) with 15% per shareholder group cap, mitigating blocking risks vs historical SPAC failures

  • Forgent Power Solutions↓(BULLISH)
    ▲

    2026 Incentive Award Plan post-IPO aligns management incentives with shareholders, enhancing execution on debt facilities

  • Arxis↓(BULLISH)
    ▲

    FAA/DoD aerospace certifications and international expansion potential outweigh listed risks, positioning for defense sector tailwinds

  • Artelo Biosciences↓(BULLISH)
    ▲

    ELOC commitment expandable to $50M (initial $25M) provides flexible capital despite limits (30% daily volume or $500K), vs pre-split distress

  • Research Alliance Corp III↓(BULLISH)
    ▲

    One-third ordinary shares quorum for business combination votes streamlines approvals vs higher thresholds in peers

  • Forgent Power Solutions↓(NEUTRAL)
    ▲

    Multiple secured debt facilities (2023/2025 Term Loans, revolvers) support operations post-acquisitions, with related party transactions disclosed transparently

  • Artelo Biosciences↓(BULLISH)
    ▲

    Pre-funded warrants exercisable cashless at $0.003 (no expiration) offer low-cost upside exposure post-reverse split

  • Arxis↓(NEUTRAL)
    ▲

    Detailed risk disclosures reflect mature compliance framework, potentially aiding IPO valuation stability vs less transparent peers

Risk Flags(10)

Opportunities(10)

Sector Themes(6)

  • SPAC Standardization Revival(BULLISH IMPLICATION)
    ◆

    Research Alliance mirrors peers with 24-month timelines, 15% redemption caps, 34% thresholds – 1/4 filings bullish for de-SPAC efficiency amid IPO pickup

  • Power Sector Acquisition Momentum(MIXED IMPLICATION)
    ◆

    FPS intangibles (backlog/trade names from 4 deals) vs no peers; layered debt supports growth but flags concentration (Q4 2025 single customer)

  • Biotech Distress Signaling(BEARISH IMPLICATION)
    ◆

    Artelo's 65% share reduction via reverse split, ELOC dilution, Nasdaq extension contrasts neutral peers – watch for sector contagion

  • Aerospace Regulatory Overhang(BEARISH IMPLICATION)
    ◆

    Arxis (sole filing) lists FAA/DoD/ITAR/FCPA risks intensifying with expansion; negative sentiment highest (vs 3/4 neutral/mixed) pressures IPO multiples

  • Post-IPO Disclosure Surge(NEUTRAL IMPLICATION)
    ◆

    FPS Feb 6 closing + over-allotment/plan details in 1/4 filings highlight transition risks/rewards, with 100% high materiality (9-10/10)

  • Dilution as Capital Lifeline(MIXED IMPLICATION)
    ◆

    Artelo ELOC/bridge/warrants (2/10 total signals bearish) vs FPS debt; mixed across distressed vs stable issuers

Watch List(8)

Filing Analyses(4)
Research Alliance Corp IIIS-1neutralmateriality 9/10

24-03-2026

Research Alliance Corp III, a SPAC, filed an S-1 registration statement on March 24, 2026, for an IPO of 5,000,000 public Class A ordinary shares with the trust account initially anticipated at $10.00 per public share. Public shareholders have redemption rights upon consummation of an initial business combination, requiring approval from 1,711,324 public shares (34.2% of 5M shares assuming full vote and no over-allotment), with a 15% redemption limit per shareholder group (or affiliates) without consent to prevent blocking deals. The SPAC has 24 months from IPO closing to complete a business combination, with sponsor and management waiving redemption rights.

  • ·Tender offer for redemptions must remain open for at least 20 business days if conducted under SEC tender offer rules.
  • ·SPAC has 24 months from IPO closing to complete initial business combination or redeem 100% of public shares.
  • ·One-third of issued ordinary shares constitutes quorum for shareholder vote on business combination.
  • ·Sponsor and management team agreed to vote founder shares, private placement shares, and any public shares in favor of business combination.
Forgent Power Solutions, Inc.S-1neutralmateriality 10/10

24-03-2026

Forgent Power Solutions, Inc. (FPS) filed an S-1 registration statement on March 24, 2026, disclosing its corporate structure involving parent entities like Forgent Parent LPs and subsidiaries such as Forgent Intermediate LLC and Opco LLC, along with acquisitions including PwrQ, States, VanTran, and MGM contributing to intangible assets like customer relationships, trade names, and backlog. The filing details multiple secured debt facilities (e.g., 2023 Term Loan, 2025 Term Loan, revolving facilities) and related party transactions including revenue, expenses, sponsor fees, and operating leases. Subsequent events reference an IPO closing on February 6, 2026, private placements, over-allotment options on February 9, 2026, and a 2026 Incentive Award Plan, with noted customer concentration risk from one customer in Q4 2025.

  • ·Customer concentration risk: One customer represented significant revenue and accounts receivable in Q4 2025 (Oct-Dec 2025).
  • ·Intangible assets include customer relationships, trade names, order/production backlog, noncompete agreements, trademarks from acquired entities.
  • ·Multiple debt facilities: 2023 Term Loan Facility, 2023 Revolving Facility, 2025 Term Loan Facility, Initial Term Facility, Delayed Term Loan, 2024 Term Loan.
  • ·Related party involvement in operating leases, sponsor fees/expenses, revenue, and expenses across periods.
Arxis, Inc.S-1negativemateriality 9/10

24-03-2026

Arxis, Inc. filed an S-1 registration statement with the SEC on March 24, 2026, ahead of its proposed IPO, detailing extensive risk factors such as potential adverse opinions on internal controls over financial reporting, compliance burdens from data privacy, anti-corruption laws like FCPA and UK Bribery Act, conflict minerals disclosures, aerospace certifications by FAA and DoD, export controls under ITAR and EAR, product liability, ongoing litigation, employee misconduct risks, and environmental liabilities. These risks could result in significant fines, penalties, contract losses, debarment, reputational damage, and material adverse effects on business operations and Class A common stock trading price/liquidity. The disclosures emphasize heightened exposure as international operations expand, with no mitigating financial or operational positives noted in this excerpt.

ARTELO BIOSCIENCES, INC.S-1mixedmateriality 9/10

24-03-2026

Artelo Biosciences filed an S-1 on March 24, 2026, to register resale of shares under a January 30, 2026 ELOC Purchase Agreement with Square Gate for up to $25M initial commitment (expandable to $50M), issuing $500K in commitment shares/warrants that cause dilution and potential stock price pressure. The company effected a 1-for-3 reverse stock split on March 10, 2026, reducing outstanding shares from 2.12M to 736K amid Nasdaq delisting risks, and issued a $237K 12% bridge note (for $210K net) on March 12, 2026; however, Nasdaq granted a compliance extension to March 30, 2026, for $2.5M minimum equity while reconvening its annual meeting on January 30, 2026, with only 50.4% quorum.

  • ·ELOC puts limited to lesser of 100% 5-day avg daily volume, 30% daily volume, or $500K.
  • ·Bridge note convertible at greater of $0.125 or 75% of lowest 10-day trading price upon default.
  • ·Pre-funded warrants exercisable at $0.003 per share (cashless, no expiration).
  • ·Nasdaq annual meeting deficiency cured via January 30, 2026 reconvened meeting.
  • ·Prohibited from variable rate transactions during ELOC standstill periods.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 4 filings

Subscribe nowBrowse all digests

🇺🇸 More from United States

View all →

March 26, 2026

US Pre-Market SEC Filings Roundup — March 26, 2026

US Pre-Market SEC Filings Roundup

March 25, 2026

US Pre-Market SEC Filings Roundup — March 25, 2026

US Pre-Market SEC Filings Roundup

March 25, 2026

Biotech Small-Cap Approvals — March 25, 2026

Biotech Small-Cap Approvals

March 25, 2026

New Drug Approvals (Original) — March 25, 2026

New Drug Approvals (Original)

← All United States digests
US IPO Pipeline SEC S-1 Filings — March 24, 2026 | Gunpowder Blog